1. Home
  2. LAC vs OCS Comparison

LAC vs OCS Comparison

Compare LAC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$3.03

Market Cap

1.6B

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

HOLD

Current Price

$11.76

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
OCS
Founded
2023
2003
Country
Canada
Switzerland
Employees
N/A
60
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LAC
OCS
Price
$3.03
$11.76
Analyst Decision
Hold
Strong Buy
Analyst Count
7
6
Target Price
$6.14
$42.00
AVG Volume (30 Days)
9.4M
473.1K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$466.06
Revenue Next Year
N/A
$479.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.47
$10.52
52 Week High
$10.52
$34.48

Technical Indicators

Market Signals
Indicator
LAC
OCS
Relative Strength Index (RSI) 26.61 33.22
Support Level N/A $10.52
Resistance Level $4.04 $21.82
Average True Range (ATR) 0.18 0.72
MACD -0.03 0.19
Stochastic Oscillator 14.71 7.88

Price Performance

Historical Comparison
LAC
OCS

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Share on Social Networks: